Nutritional Supplement for Cancer Patients is Undergoing First Clinical Trial
A nutritional supplement is being tested in a clinical study as an adjuvant therapy to determine if it can enhance survival and quality of life in patients with advanced and metastatic cancers. Early results demonstrate that Lipoic Acid Palladium Complex (LAPd) does prolong cancer remissions.
(PRWEB) May 25, 2005 -- A nutritional supplement reported to provide some
cancer patients with better quality of life and, in some cases, prolonged
remissions is undergoing its first clinical trial as an adjuvant therapy for
cancer. This supplement, Lipoic Acid Palladium Complex (LAPd), was created by
Dr. Merrill Garnett, a chemist who spent over 20 years in search of a non-toxic
form of chemotherapy that could be used to support more orthodox treatments. His
search led to the creation of a proprietary blend of lipoic acid, palladium,
vitamins B1, B2 and B12, and specific trace minerals and amino acids. Over the
last several years a growing number of cancer patients, many with advanced and
metastatic disease have used it as a nutritional supplement. Many claim that
they have derived a benefit. Today, LAPd, under the brand name Poly-MVA (stands
for "Poly Minerals, Vitamins, and Amino Acids"), is undergoing evaluation as an
adjuvant therapy for cancer in a clinical study by James W. Forsythe M.D.,
H.M.D. Early results suggest that, in combination with chemotherapy, it does
provide patients with grade IV and metastatic cancers with a remission
advantage.
Dr. Forsythe explained, "After nine months we had accrued 106
patients and the overall response rate was 77% which means that a little over
three-quarters of the patients had either a complete response (all the cancer
had disappeared) or a partial response (50% or more of the cancer had
disappeared). My conclusion thus far is that Lipoic Acid Palladium Complex is a
safe and efficacious adjuvant to either add to chemo or to administer to
patients who do not want any further chemo or who have been through all the
chemotherapy that is reasonably effective."
Mark Olsztyn was diagnosed
with an aggressive brain tumor called oligodendroglioma grade IV in March of
1997 when he was 32 years old. This type of tumor is invariably fatal. Mr.
Olsztyn used orthodox treatments (surgery, radiation therapy, and some
chemotherapy), but these treatments are generally palliative (focused on symptom
management). To enhance his chances of survival, Mr. Olsztyn began taking
Poly-MVA immediately after his surgery and has been taking it every day for the
last eight years. During this time, he has not had the tumor recur. Mr. Olsztyn
believes that LAPd has played a role in his exceptional remission. "Orthodox
treatments alone with my type of cancer are scarcely ever successful and I was
told if I stopped chemo that I would die. Well, I stopped chemo over seven years
ago and I’m still here. Doctors now tell me to keep on doing whatever it is that
I’m doing because it seems to be working," Mr. Olsztyn explained.
Dr.
Antonawich an Associate Professor of Neurology at State University of New York
at Stony Brook and Chairperson and Associate Professor of Biology at Saint
Josephs College, New York completed some of the first safety studies on LAPd and
is now studying the biological mechanisms of what this molecule does to cancer
cells. He believes that LAPd kills cancer cells and leaves healthy cells alone
because it’s action depends on the oxygen consumption of the tissue and cancer
cells have low oxygen. "When Lipoic Acid Palladium Complex is introduced into
cells that do not have sufficient oxygen, electrons are being added but these
electrons will get backed-up and generate free radicals. These free radicals
will in turn initiate apoptosis. In healthy cells the electrons will be grabbed
by oxygen creating water molecules so free radicals are not created," Dr.
Antonawich explained.
More information:
· To read the full story http://www.cancermonthly.com
· To subscribe to CancerWire
http://www.cancermonthly.com/cancerwire.asp
· To enroll in
Dr. Forsythe’s study, his clinic may be reached at 775-827-3533 or 775-827-0707.
· To Purchase Poly-MVA http://www.polymva.net/
· For more information about immune
boosting products in cancer http://www.cancermonthly.com/immune.asp
· For more
information about clinics that treat cancer http://www.cancermonthly.com/clinics.asp
· For more
information about financial support for cancer patients http://www.cancermonthly.com/financial.asp
· For more
information about important tests before you start chemotherapy http://www.cancermonthly.com/chemotherapy.asp
· For more
information about legal options for mesothelioma patients http://www.gpwlaw.com/cm/
Of course, none of this
information in CancerWire is a substitute for professional medical advice,
examination, diagnosis or treatment and you should always seek the advice of
your physician or other qualified health professional before starting any new
treatment or making any changes to an existing treatment. No information
contained in Cancer Monthly or CancerWire including the information above,
should be used to diagnose, treat cure or prevent any disease without the
supervision of a medical doctor.
# # #
Source : http://www.prweb.com/releases/2005/5/prweb243972.htm